Paclitaxel Poliglumex

Ovarian Serous Cystadenocarcinoma

Gynecologic Oncology GroupPhase 1Dormant

CC

44/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 29/ 100
Competitive Position: 95/ 100

Competitive context

6 Active assets in the Ovarian Serous Cystadenocarcinoma cohort.

Asset / Sponsor	Phase	Rating
Carboplatin National Cancer Institute (NCI)	Phase 2	BB
Metformin University of Chicago	Phase 2	BB
FILGRASTIM University of Washington	Phase 2	B
Hycamtin Gynecologic Oncology Group	Phase 2	B
Cyclophosphamide National Cancer Institute (NCI)	Phase 2	B

View all 31 →

Same molecule, other indications

Paclitaxel Poliglumex is also rated in:

Primary Peritoneal CarcinomaDormant

B

Indicative ·

60 / 100

Malignant Ovarian Mixed Epithelial TumorDormant

B

Indicative ·

56 / 100

Ovarian Brenner TumorDormant

B

Indicative ·

56 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.